# Slit-based Irrigation Catheters can Reduce Procedure-related Ischemic Stroke in Atrial Fibrillation Patients Undergoing Radiofrequency Catheter Ablation

Yun Gi Kim<sup>1</sup>, Jaemin Shim<sup>1</sup>, Ki-Yung Boo<sup>2</sup>, Do-Young Kim<sup>2</sup>, Kwang-No Lee<sup>1</sup>, Jong-Il Choi<sup>3</sup>, and Young-Hoon Kim<sup>4</sup>

<sup>1</sup>Korea University Anam Hospital <sup>2</sup>Korea University <sup>3</sup>Korea University Medical Center <sup>4</sup>Korea University Medical Centrer

April 28, 2020

#### Abstract

Introduction: Open irrigation ablation catheters are now the standard in radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF). Among various irrigation catheters, laser-cut slit-based irrigation system (Cool Flex and FlexAbility) has a unique design to cool the catheter tip more efficiently. We aimed to assess the safety of slit-based irrigation catheters regarding prevention of procedure-related ischemic complication in AF patients undergoing RFCA. Methods and Results: The analysis was performed with Korea University Medicine Anam Hospital RFCA registry. Procedure-related ischemic complication was defined as ischemic stroke or transient ischemic attack (TIA) occurring within 30 days after RFCA. Patients were divided into 3 groups: non-irrigation, hole-based irrigation, and slit-based irrigation catheter groups. A total of 3,120 AF patients underwent first RFCA. Non-irrigation, non-slit-based irrigation, and slit-based irrigation catheters were used in 290, 1,539, and 1,291 patients, respectively. As compared with non-irrigation and non-slit-based irrigation catheter groups, slit-based irrigation catheter group had significantly older age, higher prevalence of non-paroxysmal AF, large left atrial size, and decreased left atrial appendage flow velocity. The CHA2DS2-VASc score was not different among the 3 groups. Procedure-related ischemic complication occurred in 17 patients (0.54%) with 16 ischemic strokes and 1 TIA event: 5/290 (1.72%), 11/1,539 (0.71%), and 1/1,291 (0.08%) events in non-irrigation, non-slit-based irrigation, and slit-based irrigation catheter groups, respectively (p = 0.001). Slit-based irrigation catheter was superior in direct comparison with non-slit-based irrigation catheter (0.71% vs.)0.08%; p = 0.009). Conclusions: Slit-based irrigation catheters were highly effective in preventing procedure-related ischemic complications.

## 1. Introduction

Radiofrequency catheter ablation (RFCA) for symptomatic atrial fibrillation (AF) is an established treatment which is associated with significantly improved quality of life.<sup>1</sup> Recent clinical trials also suggest that RFCA can improve not only quality of life but also hard clinical outcomes including all cause death in patients with both AF and heart failure.<sup>2, 3</sup> Claim data based retrospective data also suggest that RFCA is associated with reduced risk of ischemic stroke.<sup>4, 5</sup> Despite various benefits of RFCA in AF patients, RFCA is associated with several catastrophic complications such as procedure-related stroke or atrio-esophageal fistula.<sup>6</sup>

Time interval between occurrence of procedure-related stroke and correct diagnosis due to patient sedation delays appropriate therapy and significant proportion of patients with procedure-related stroke have permanent neurologic consequences. Optimal treatment modalities for procedure-related stroke are also not established since majority of these strokes are due to char formation during radiofrequency energy delivery.<sup>7, 8</sup> Char formation during radiofrequency energy delivery is thought to be related with tissue overheating and acute cellular damage.<sup>9</sup>Irrigation catheters were developed in order to reduce tissue overheating and char formation.<sup>10-12</sup> Among irrigation catheters, open-irrigation catheters showed lower interface temperature, thrombus, and steam pop compared with closed-loop irrigation catheters indicating greater interface cooling capability.<sup>13</sup>Open-irrigation catheters are further classified according to their shape: 6-holes, 12-holes, 56-holes, and slit-based irrigation system. Slit-based irrigation catheters have the largest irrigation space compared to other open-irrigation catheters. However, whether slit-based irrigation catheters are superior to other open-irrigation catheters in terms of stroke prevention remains largely unknown. We aimed to compare the risk of procedure-related ischemic complication among non-irrigation, non-slit-based irrigation, and slit-based irrigation catheters.

## 2. Methods

## 2.1 Patients

Consecutive AF patients undergoing RFCA at Korea University Medicine Anam Hospital between June 1998 and April 2019 were analyzed retrospectively. A total of 3,120 patients underwent their first RFCA for AF during the study period. There was no specific exclusion criteria and all patients who underwent their firsttime RFCA in our institution were included. This study was approved by the Institutional Review Board of Korea University Medicine Anam Hospital. Written informed consent was waived due to the retrospective nature of the current study. The study protocol adheres to the ethical guidelines of the 2008 Declaration of Helsinki.

## 2.2 Ablation procedure and anticoagulation

The precise protocol for RFCA in our institution is published elsewhere.<sup>6</sup>Pre-procedural anticoagulation was performed with either warfarin or non-vitamin K oral anticoagulant (NOAC). Some patient was not prescribed with anticoagulants. However, we performed transesophageal echocardiography (TEE) in 92.9% of patients to rule out any thrombus or sludge in left atrium (LA) of left atrial appendage (LAA). Emptying, filling, and average flow velocity of the LAA were measured during TEE evaluation. Protocols of our pre-procedural imaging evaluation are published elsewhere.<sup>14</sup>Either computed tomography (CT) or magnetic resonance imaging (MRI) study was performed to assess the anatomy of the pulmonary veins and to create a three-dimensional reconstruction map using either EnSite NavX or CARTO systems. During RFCA, intravenous heparin was administered to maintain activated coagulation time between 300 – 350 seconds.

After index RFCA, anticoagulation with either warfarin or NOAC was performed for at least two months after the procedure. After two months, anticoagulation therapy was given to patients with CHA<sub>2</sub>DS<sub>2</sub>-VASc score [?] 2. Anticoagulation was discontinued, at the operator's discretion, if no AF was documented on regular Holter monitoring (every 3 months for the first year and every 6 months thereafter).

#### 2.3 Definitions

Procedure-related ischemic complication was defined as any ischemic stroke or transient ischemic attack (TIA) which occurred within 30 days post-RFCA. Immediate procedure-related ischemic complication was defined as ischemic stroke or TIA within 3 days post-RFCA.

Ischemic stroke was defined as any neurologic symptom that persisted for more than 24 hours which could not be explained by other medical conditions. Transient ischemic attack was defined as any neurologic symptom that was not attributable to other medical cause, but resolved completely within 24 hours. If acute infarction was observed on brain CT or MRI, the event was classified as ischemic stroke despite complete restoration of neurologic symptoms. Neurologists confirmed the final diagnosis of ischemic stroke and TIA. Neurologic consequence of procedure-related stroke was classified into three stages: (i) None: no neurologic symptoms; (ii) Minimal: permanent neurologic symptoms which does not limit normal daily life; (ii) Significant: permanent neurologic symptoms which have significant limitation on normal daily life or occupation.

#### 2.4 Irrigation system

Irrigation system of ablation catheters were classified into three groups: non-irrigation, non-slit-based irrigation, and slit-based irrigation catheters. Non-slit-based irrigation catheters included closed-loop irrigation catheters and hole-based open-irrigation catheters. Slit-based irrigation catheters were consisted of Cool Flex and FlexAbility catheter (Abbott, Chicago, IL, USA). Flow rate of the irrigation fluid was based on the manufacturer's recommendations.

#### **3** Statistical analysis

Continuous variables are expressed as mean  $\pm$  standard deviation. Categorical variables are presented as percentile value. Unpaired t-test was used to compare continuous variables. Categorical variables were compared using either the chi-square test or Fisher's exact test, as appropriate. Multivariate logistic regression analysis was performed to evaluate the impact of different type of irrigation system on procedure-related ischemic complications. Covariates included in the multivariate model were chosen based on the baseline characteristics of each group and univariate logistic regression analysis. However, the known risk factors of ischemic stroke or TIA, such as individual components of the CHA<sub>2</sub>DS<sub>2</sub>-VASc score, were included in multivariate analysis regardless of the results of univariate analysis. Results were considered to be significant if the p-value was <0.05 on a two-tailed test. All statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Armonk, NY, USA).

#### 4 Results

### 4.1 Patients

During June 1998 to April 2019, a total of 3,120 patients underwent their first RFCA for AF with 290 non-irrigation, 1,539 non-slit-based irrigation, and 1,291 slit-based irrigation ablation catheters. Baseline characteristics of the entire cohort are summarized in Table 1. Mean age was 55.74  $\pm$  10.96 years and 78.9% were male. Previous history of thromboembolic events was observed in 8.4% of the patients and mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was 1.27  $\pm$  1.26.

## 4.2 Procedure-related ischemic complication

Procedure-related ischemic complication occurred in 17 patients: six patients had no permanent neurologic consequences and five patients had permanent neurologic symptoms which significantly limited their normal daily life. Mean CHA<sub>2</sub>DS<sub>2</sub>-VASc score was  $1.35 \pm 1.12$  and 14 patients were male. Eleven (64.7%) patients had non-paroxysmal AF and substrate modification in addition to pulmonary vein isolation was performed in 64.7% of patients. Characteristics of these 17 patients with procedure-related stroke are summarized in Table 2. Baseline characteristics of patients with and without procedure-related stroke are compared in Table 1. Patients with procedure-related ischemic complication had larger LA diameter (44.38  $\pm$  5.44 vs. 41.18  $\pm$  6.04 mm; p = 0.035), higher proportion of non-paroxysmal AF (64.7% vs. 40.8%; p = 0.046).

Distribution of patients who were treated with antiplatelets, warfarin, NOAC, or no antithrombotic agents before and after RFCA is depicted in Figure 1A, B. Type of antithrombotic medication did not affect the incidence of procedure-related ischemic complication (p = 0.261 for pre-RFCA and 0.810 for post-RFCA; Figure 2C, D).

### 4.3 Irrigation system

Baseline characteristics of patients who were ablated with slit-based irrigation (n = 1,291) vs. other catheters (n = 1,829) are summarized in Table 3. Those who were ablated with slit-based irrigation catheter were older (56.65  $\pm$  10.62 vs. 55.10  $\pm$  11.15 years; p < 0.001); had larger LA (41.63  $\pm$  6.18 vs. 40.89  $\pm$  5.93 mm; p = 0.001); lower LAA flow velocity (46.59  $\pm$  21.63 vs. 50.08  $\pm$  21.15 cm/sec; p < 0.001); and higher prevalence of SEC (17.0% vs. 21.5%; p = 0.002) and non-paroxysmal AF (45.5% vs. 37.7%; p < 0.001).

One procedure-related ischemic complication occurred in patients who were ablated with slit-based irrigation (0.08%) whereas 16 events occurred in patients ablated with other catheters (0.87%; p = 0.003; Figure

3A). When classified into three groups, non-irrigation catheters had highest incidence of procedure-related ischemic complication (1.72%) followed by non-slit-based irrigation catheters (0.71%) and slit-based irrigation catheters (0.08%) (p = 0.001; Figure 3B). Slit-based irrigation catheter was also superior in direct comparison with non-slit-based irrigation catheter (0.71% vs, 0.08%; p = 0.009). Incidence of immediate procedure-related ischemic complication (occurring within 3 days of post-RFCA) also differed significantly according to catheter type (Figure 3C, D). Multivariate model revealed that use of slit-based irrigation catheter was the only significant predictor of procedure-related ischemic complication (Table 4).

#### **5** Discussion

This study revealed that slit-based irrigation catheters can be effective in preventing procedure-related ischemic complication. Non-irrigation catheters showed highest risk for procedure-related ischemic complication and peri-procedural anticoagulation did not influence the risk for procedure-related ischemic complication. This data is the largest study to date analyzing safety issue of different irrigation systems and the first report demonstrating that irrigation systems can affect actual clinical stroke and TIA.

## 5.1 Ischemic complication during RFCA

Together with atrio-esophageal fistula, peri-procedural ischemic complication is most dreaded complication in AF patients undergoing RFCA.<sup>15</sup> Since patients are in deep sedation or under general anesthesia, they cannot complain any neurologic symptoms when their cerebral arteries are occluded by thrombus or char. It takes several hours to complete the procedure and to recover from sedation or general anesthesia. Therefore, immediate revascularization was often not feasible. Furthermore, char formation during radiofrequency energy delivery makes harder thrombus material which makes revascularization therapy even more difficult. Although massive thrombus and char embolization during RFCA is a rare event, it is usually unrecoverable once occurred.

In our registry, five patient had significant neurologic sequelae defined as permanent neurologic symptoms limiting their normal daily life or occupation. Making ischemic stroke during treatment process of AF is an irony and 0.16% (5 among 3,120 patients) risk of having significant neurologic sequelae cannot be ignored.

#### 5.2 Irrigation system

Local temperature elevation at the distal tip of ablation catheter during RFCA can result in temperaturedependent coagulum and char formation.<sup>9</sup> Histological review of these deposits revealed that it was consisted of denaturized and aggregated proteins rather than classical thrombus.<sup>9</sup> Therefore, reducing the temperature of distal electrode tip can potentially reduce char and thrombus formation.

In our registry, patients who were ablated with non-irrigation catheters showed highest risk of having procedure-related ischemic complication (1.72%) followed by non-slit-based irrigation (0.71%) and slit-based irrigation catheters (0.08%). Irrigation catheters were developed for two major reasons: formation of deeper lesions and reduction of ischemic complications.<sup>10</sup>Previous studies demonstrated that irrigation catheters were capable of making deeper lesions as compared with non-irrigation catheters.<sup>16, 17</sup> Although irrigation catheters, whether irrigation catheters can reduce clinical ischemic complications remains largely unknown.<sup>10</sup>

Previous study reported that irrigated tip catheter did not reduce the incidence of symptomatic periprocedural ischemic stroke.<sup>18</sup> However, the study enrolled patients from February 2001 to January 2008 where no slit-based irrigation catheters were available and our study demonstrated a lower incidence of procedurerelated ischemic complication in slit-based irrigation catheters. Our study also showed lower incidence of procedure-related ischemic complication in non-slit-based irrigation catheters compared non-irrigation catheters (0.71% vs. 1.72%). The discrepancy between the two studies can be due to small sample size or different type of non-irrigation catheter (predominantly 8mm tip in the study by Scherr et al. and 4mm tip in ours).

## 5.3 Anticoagulation

Previous studies reported that continuation of anticoagulation in peri-operative period can reduce ischemic complication after RFCA.<sup>19, 20</sup> However, pre- or post-RFCA anticoagulation did not affect the incidence of peri-procedural ischemic complication in our study. Since embolic material formed by catheter ablation is mainly consisted of denaturized and aggregated proteins rather than classical thrombus, peri-procedural ischemic complication can still occur despite optimal anticoagulation therapy.<sup>9</sup> Indeed, heat induced protein denaturation and aggregation occurred independently from heparin concentration.<sup>9</sup>Nevertheless, optimal anticoagulation therapy should be done in peri-procedural period since denaturized material formed by radiofrequency energy can activate coagulation cascade. Both irrigation and anticoagulation are essential.

## 6 Limitations

Our results are based on retrospective analysis and therefore, are not free from intrinsic limitation of such analysis. Although total patient number was large, the number of peri-procedural ischemic complication was small limiting statistical power. Slit-based irrigation catheters cannot sense contact force which should be added in future models.

## 7 Conclusion

Slit-based irrigation catheters may reduce the risk of peri-procedural ischemic complication compared with non-irrigation or non-slit-based irrigation catheters. Our results should be tested in future clinical trials.

#### References

1. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: The cabana randomized clinical trial. *JAMA* . 2019;321:1275-1285.

2. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for a trial fibrillation with heart failure. *N Engl J Med* . 2018;378:417-427.

3. Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: Results from the aatac multicenter randomized trial. *Circulation*. 2016;133:1637-1644.

4. Friberg L, Tabrizi F, Englund A. Catheter ablation for a trial fibrillation is associated with lower incidence of stroke and death: Data from swedish health registries. *Eur Heart J* . 2016;37:2478-2487.

5. Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of a trial fibrillation and the risk of thromboembolism and serious bleeding: Long-term follow-up in nation wide cohort of denmark. *Eur Heart J* . 2015;36:307-314a.

6. Kim YG, Shim J, Kim DH, et al. Characteristics of atrial fibrillation patients suffering atrioesophageal fistula after radiofrequency catheter ablation. *J Cardiovasc Electrophysiol* . 2018;29:1343-1351.

7. Wazni OM, Rossillo A, Marrouche NF, et al. Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: Impact of different anticoagulation regimens and importance of intracardiac echo imaging. *J Cardiovasc Electrophysiol*. 2005;16:576-581.

8. Zhou L, Keane D, Reed G, et al. Thromboembolic complications of cardiac radiofrequency catheter ablation: A review of the reported incidence, pathogenesis and current research directions. *J Cardiovasc Electrophysiol*. 1999;10:611-620.

9. Demolin JM, Eick OJ, Munch K, et al. Soft thrombus formation in radiofrequency catheter ablation. *Pacing Clin Electrophysiol* . 2002;25:1219-1222.

10. Waldo AL, Wilber DJ, Marchlinski FE, et al. Safety of the open-irrigated ablation catheter for radiofrequency ablation: Safety analysis from six clinical studies. *Pacing Clin Electrophysiol*. 2012;35:1081-1089.

11. Kanj MH, Wazni O, Fahmy T, et al. Pulmonary vein antral isolation using an open irrigation ablation

catheter for the treatment of a trial fibrillation: A randomized pilot study.  $J\,Am\,\,Coll\,\,Cardiol$  . 2007; 49:1634-1641.

12. Thomas SP, Aggarwal G, Boyd AC, et al. A comparison of open irrigated and non-irrigated tip catheter ablation for pulmonary vein isolation. *Europace*. 2004;6:330-335.

13. Yokoyama K, Nakagawa H, Wittkampf FH, et al. Comparison of electrode cooling between internal and open irrigation in radiofrequency ablation lesion depth and incidence of thrombus and steam pop. *Circulation* . 2006;113:11-19.

14. Kim YG, Choi JI, Kim MN, et al. Non-vitamin k antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study. *PLoS One* . 2018;13:e0191648.

15. Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: A cause of silent thromboembolism? Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. *Circulation* . 2010;122:1667-1673.

16. Guerra JM, Jorge E, Raga S, et al. Effects of open-irrigated radiofrequency ablation catheter design on lesion formation and complications: In vitro comparison of 6 different devices. *J Cardiovasc Electrophysiol* . 2013;24:1157-1162.

17. Weiss C, Antz M, Thuneke F, et al. Radiofrequency catheter ablation using long coiled electrodes: Impact of irrigation on lesion dimensions and incidence of coagulum formation. *Pacing Clin Electrophysiol* . 2001;24:933-938.

18. Scherr D, Sharma K, Dalal D, et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol . 2009;20:1357-1363.

19. Kuwahara T, Takahashi A, Takahashi Y, et al. Prevention of periprocedural ischemic stroke and management of hemorrhagic complications in atrial fibrillation ablation under continuous warfarin administration. J Cardiovasc Electrophysiol . 2013;24:510-515.

20. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. *Circulation* . 2010;121:2550-2556.

#### Abbreviations

AF: atrial fibrillation; CT: computed tomography; MRI: magnetic resonance imaging; NOAC: non-vitamin K oral anticoagulant; LA: left atrium; LAA: left atrial appendage; RFCA: Radiofrequency catheter ablation; TEE: transesophageal echocardiography; TIA: transient ischemic attack.

## Author contribution statement

J. Shim had full access to all data in this study and takes responsibility for data integrity and analytical accuracy. Concept and design of the study was made by Y. G. Kim, J. Shim, and Y. H. Kim. Data analysis and interpretation was performed by Y. G. Kim, K. Y. Boo, D. Y. Kim, K. N. Lee, and J. I. Choi. Drafting article was done by Y. G. Kim. Statistical analysis was performed by Y. G. Kim. Data collection was performed by Y. G. Kim, K. Y. Boo, D. Y. Kim, J. I. Choi, and Y. H. Kim.

**Funding source:** This work was supported by a grant from Korea University Anam Hospital, Seoul, Republic of Korea (grant No. K1922851).

Competing interest statement: The authors have nothing to disclose

#### Figure Legends

Figure 1. Pre- and post-RFCA antithrombotic therapy.

(A) Type of antithrombotic therapy received before RFCA.

(B) Type of antithrombotic therapy received after RFCA.

Abbreviations are the same as in the text.

Figure 2. Incidence of peri-procedural ischemic complication according to antithrombotic therapy.

(A) Incidence of peri-procedural ischemic complication according to type of antithrombotic therapy received before RFCA.

(B) Incidence of peri-procedural ischemic complication according to type of antithrombotic therapy received before RFCA.

Abbreviations are the same as in the text.

Figure 3. Incidence of peri-procedural ischemic complication according to catheter type.

(A, B) Incidence of peri-procedural ischemic complication according to catheter type.

(C, D) Incidence of immediate peri-procedural ischemic complication according to catheter type.

Table 1. Baseline characteristics of the study population.

|                                    | Total N = $3,120$ | Procedure-<br>related ischemic<br>complication (-) | Procedure-<br>related ischemic<br>complication $(+)$ | p value |
|------------------------------------|-------------------|--|--|---------|
|                                    |                   | n = 3,103  | n = 17   |         |
| Age (year)                         | $55.74 \pm 10.96$ | $55.72 \pm 10.97$                                  | $59.29 \pm 7.94$                                     | 0.180   |
| LA diameter<br>(mm)                | $41.20 \pm 6.04$  | $41.18 \pm 6.04$                                   | $44.38 \pm 5.44$                                     | 0.035   |
| Body mass                          | $24.98 \pm 3.07$  | $24.98 \pm 3.07$                                   | $24.90 \pm 2.41$                                     | 0.912   |
| index $(kg/m^2)$                   |                   |  |  |         |
| CHA <sub>2</sub> DS <sub>2</sub> - | $1.27 \pm 1.26$   | $1.27 \pm 1.27$                                    | $1.35 \pm 1.12$                                      | 0.790   |
| VASc                               |                   |  |  |         |
| LV ejection                        | $54.68 \pm 6.14$  | $54.68 \pm 6.13$                                   | $53.46 \pm 6.84$                                     | 0.425   |
| fraction (%)                       |                   |  |  |         |
| E/e'                               | $8.79 \pm 3.79$   | $8.78 \pm 3.80$                                    | $10.10 \pm 2.28$                                     | 0.273   |
| LAA flow                           | $48.53 \pm 21.43$ | $48.58 \pm 21.43$                                  | $38.80 \pm 19.98$                                    | 0.078   |
| velocity                           |                   |  |  |         |
| $(\mathrm{cm/sec})$                |                   |  |  |         |
| SEC                                | 19.5%             | 19.4%  | 40.0%  | 0.093   |
| Non-                               | 40.9%             | 40.8%  | 64.7%  | 0.046   |
| paroxysmal<br>AF                   |                   |  |  |         |
| Male sex                           | 78.9%             | 78.9%  | 82.4%  | 0.725   |
| Heart failure                      | 6.5%              | 6.5%   | 5.9%   | > 0.999 |
| Hypertension                       | 38.0%             | 38.1%  | 35.3%  | 0.815   |
| Diabetes                           | 9.6%              | 9.6%   | 5.9%   | > 0.999 |
| Stroke or TIA                      | 8.4%              | 8.3%   | 17.6%  | 0.165   |
| history                            | 0                 | 0.070  | ,  | 0.200   |
| Vascular                           | 7.7%              | 7.7%   | 5.9%   | > 0.999 |
| disease                            |                   |  |  |         |
| Substrate                          | 45.5%             | 45.5%  | 62.5%  | 0.172   |
| modification                       |                   |  |  |         |
| Pre-RFCA                           | 60.4%             | 60.3%  | 82.4%  | 0.064   |
| anticoagulation                    |                   |  |  |         |

| Post-RFCA       | 95.0% | 95.0% | 100.0% | > 0.999 |
|-----------------|-------|-------|--------|---------|
| anticoagulation |       |       |        |         |

Abbreviations are the same as in the text.

 Table 2. Patients who experienced peri-procedural ischemic complication.

|    | RFCA Date  | Stroke / TIA | Neurologic sequela | Age            | Sex   | Non-Paroxysmal | CHA <sub>2</sub> DS <sub>2</sub> -V |
|----|------------|--------------|--------------------|----------------|-------|----------------|-------------------------------------|
| 1  | 2000-04-17 | Stroke       | Minimal            | 61             | М     | 0              | 0                                   |
| 2  | 2003-03-14 | Stroke       | Significant        | 53             | F     | 0              | 2                                   |
| 3  | 2005-11-14 | Stroke       | Minimal            | 42             | Μ     | 1              | 0                                   |
| 4  | 2005-12-08 | Stroke       | Minimal            | 66             | Μ     | 1              | 2                                   |
| 5  | 2006-02-20 | Stroke       | None               | 52             | Μ     | 1              | 3                                   |
| 6  | 2006-03-15 | Stroke       | Minimal            | 70             | Μ     | 0              | 2                                   |
| 7  | 2006-05-29 | Stroke       | Significant        | 60             | Μ     | 1              | 0                                   |
| 8  | 2008-12-10 | Stroke       | None               | 72             | F     | 0              | 2                                   |
| 9  | 2011-02-21 | Stroke       | Significant        | 67             | Μ     | 0              | 1                                   |
| 10 | 2012-06-07 | Stroke       | None               | 50             | Μ     | 1              | 2                                   |
| 11 | 2013-05-28 | Stroke       | Significant        | 55             | Μ     | 1              | 0                                   |
| 12 | 2013-06-18 | Stroke       | Minimal            | 57             | Μ     | 1              | 0                                   |
| 13 | 2017-04-06 | Stroke       | Minimal            | 57             | Μ     | 1              | 1                                   |
| 14 | 2017-04-13 | Stroke       | None               | 60             | Μ     | 1              | 1                                   |
| 15 | 2017-10-18 | TIA          | None               | 70             | F     | 0              | 3                                   |
| 16 | 2018-08-16 | Stroke       | None               | 58             | Μ     | 1              | 3                                   |
| 17 | 2019-02-14 | Stroke       | Significant        | 58             | М     | 1              | 1                                   |
|    |            |              | -                  | $59.29\pm7.94$ | 82.4% | 64.7%          | $1.35\pm1.12$                       |

Abbreviations are the same as in the text.

Table 3. Baseline characteristics of the study population according to ablation catheter used.

|  | Slit-based Irrigation n<br>= $1,291$ | Other catheters $n = 1,829$ | p value |
|--|--------------------------------------|-----------------------------|---------|
| Age (years)                            | $56.65 \pm 10.62$                    | $55.10 \pm 11.15$           | < 0.001 |
| LA diameter (mm)                       | $41.63 \pm 6.18$                     | $40.89 \pm 5.93$            | 0.001   |
| Body mass index                        | $25.01 \pm 3.10$                     | $24.96 \pm 3.05$            | 0.608   |
| $(kg/m^2)$                             |                                      |                             |         |
| CHA <sub>2</sub> DS <sub>2</sub> -VASc | $1.25 \pm 1.22$                      | $1.29 \pm 1.29$             | 0.425   |
| LV ejection fraction                   | $54.52 \pm 5.93$                     | $54.80 \pm 6.28$            | 0.213   |
| (%)                                    |                                      |                             |         |
| È/e'                                   | $8.78\pm3.27$                        | $8.79 \pm 4.18$             | 0.931   |
| LAA flow velocity                      | $46.59 \pm 21.63$                    | $50.08 \pm 21.15$           | < 0.001 |
| (cm/sec)                               |                                      |                             |         |
| SEC                                    | 17.0%                                | 21.5%                       | 0.002   |
| Non-paroxysmal AF                      | 45.5%                                | 37.7%                       | < 0.001 |
| Male sex                               | 78.9%                                | 78.9%                       | > 0.999 |
| Heart failure                          | 5.9%                                 | 7.0%                        | 0.216   |
| Hypertension                           | 36.9%                                | 38.8%                       | 0.289   |
| Diabetes                               | 9.0%                                 | 10.1%                       | 0.316   |
| Stroke or TIA                          | 8.7%                                 | 8.1%                        | 0.599   |
| history                                |                                      |                             |         |


| Vascular disease<br>Substrate               | 5.0%<br>44.9% | $9.6\%\ 46.0\%$ | < 0.001<br>0.562 |
|---|---------------|-----------------|------------------|
| modification<br>Pre-RFCA<br>anticoagulation | 67.3%         | 55.6%           | < 0.001          |
| Post-RFCA<br>anticoagulation                | 97.2%         | 93.5%           | < 0.001          |

Abbreviations are the same as in the text.

 Table 4. Multivariate model for procedure-related ischemic complication.


|   | Model 1 (event $n = 15$ )            | Model 1 (event $n = 15$ ) | Mode   |
|---|--------------------------------------|---------------------------|--------|
|   | HR (95% CI)                          | p value                   | HR (   |
| Slit-based irrigation catheter                  | 0.073(0.010-0.560)                   | 0.012                     | 0.071  |
| Age (year)                                      | 1.019  (0.963 - 1.080)               | 0.512                     | 1.041  |
| Sex   | $1.101  \left( 0.294 - 4.125  ight)$ | 0.886                     | 1.398  |
| Heart failure                                   | $0.575\ (0.070-4.724)$               | 0.606                     | 0.657  |
| Hypertension                                    | 0.659  (0.209 - 2.079)               | 0.477                     | 0.738  |
| Diabetes mellitus                               | $0.643\ (0.082-5.051)$               | 0.674                     | 0.535  |
| Previous ischemic stroke/TIA                    | 1.729  (0.467 - 6.404)               | 0.412                     | 1.513  |
| Vascular disease                                | $0.569\ (0.072-4.500)$               | 0.593                     | 0.468  |
| Non-paroxysmal AF                               | $1.778  \left( 0.483 - 6.547  ight)$ | 0.387                     | 2.103  |
| Left atrial diameter (mm)                       | $1.045\ (0.949-1.150)$               | 0.370                     | Not ir |
| Flow velocity of Left atrial appendage (cm/sec) | 0.991  (0.961 - 1.022)               | 0.569                     | Not ir |
| Pre-RFCA anticoagulation                        | $5.086\ (0.615 - 42.059)$            | 0.131                     | 2.334  |

Abbreviations are the same as in the text.




#### Figure 2


#### A Pre-RFCA anticoagulation




B Post-RFCA anticoagulation









C Immediate procedure-related ischemic complication ( $\leq$  3 days)

